<DOC>
	<DOCNO>NCT01122329</DOCNO>
	<brief_summary>This study examine brain metabolic effect AC-1202 ( Axona® ) , medical food Alzheimer 's disease . Subjects meet entry criterion undergo H215O positron emission tomography prior 90 minute consumption Axona® baseline 45 day treatment . Cognitive testing also conduct baseline day 45 .</brief_summary>
	<brief_title>A Positron Emission Tomography ( PET ) Study Evaluating Brain Metabolism Medical Food Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis probable AD ( NINDSADRDA criterion ( 32 ) ) Age 50 90 ( inclusive ) MMSE range : 10 28 Participants may take medication AD , provide dose medication stable &gt; 90 day Proficiency English able perform cognitive test A caregiver must available monitor administer treatment accompany subject every clinical visit . Inability reason undergo PET/CT scan Previous treatment AC1202 Allergic milk soy Presence neurodegenerative disease AD History stroke injury could result cognitive impairment Psychiatric disorder Diabetes mellitus Recent ( &lt; 90 day ) change medication prescribe cognitive reason potential impact cognition Irritable bowel syndrome ( IBS ) gastrointestinal condition could interfere treatment compliance Any factor deem investigator likely interfere study conduction</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>dementia</keyword>
</DOC>